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Abstract
Cancer affects 39.6% of Americans at some point during their lifetime. Solid tumor microen-
vironments are characterized by a disorganized, leaky vasculature that promotes regions of
low oxygenation (hypoxia). Tumor hypoxia is a key predictor of poor treatment outcome for
all radiotherapy (RT), chemotherapy and surgery procedures, and is a hallmark of meta-
static potential. In particular, the radiation therapy dose needed to achieve the same tumor
control probability in hypoxic tissue as in normoxic tissue can be up to 3 times higher. Even
very small tumors (<2–3 mm3) comprise 10–30% of hypoxic regions in the form of chronic
and/or transient hypoxia fluctuating over the course of seconds to days. We investigate the
potential of recently developed lipid-stabilized oxygen microbubbles (OMBs) to improve the
therapeutic ratio of RT. OMBs, but not nitrogen microbubbles (NMBs), are shown to signifi-
cantly increase dissolved oxygen content when added to water in vitro and increase tumor
oxygen levels in vivo in a rat fibrosarcoma model. Tumor control is significantly improved
with OMB but not NMB intra-tumoral injections immediately prior to RT treatment and effect
size is shown to depend on initial tumor volume on RT treatment day, as expected.
Introduction
Cancer affects 39.6% of Americans at some point during their lifetime [1]. Solid tumors are
characterized by the presence of disorganized, tortuous, leaky vessels that promote regions of
low oxygenation (hypoxia), Fig 1. Even small tumors (<2-3mm3) comprise 10–30% of hypoxic
regions in the form of chronic and/or transient hypoxia fluctuating over the course of seconds
to days [2, 3]. In fact, it has been shown repeatedly that hypoxia is a key factor in treatment fail-
ure and recurrence after treatments with radiotherapy (RT), chemotherapy and surgery [4–6].
Chronic exposure to this hypoxic environment selects for the most aggressive and resistant
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tumor cells, and triggers the angiogenic signaling that contributes to the overall growth of the
tumor as it develops its own blood supply network. It is therefore recognized as a hallmark of
metastatic potential [7–11].
Radiotherapy is one of the key primary treatment options for a variety of cancers and is
used in over one million cancer patients yearly in the United States [12–14]. It is well-estab-
lished that tumor hypoxia negatively impacts treatment outcome for RT [15]. In particular, the
RT dose needed to achieve the same tumor control probability in hypoxic tissue as in nor-
moxic tissue can be up to 3 times higher [4]. Hypoxia promotes radioresistance directly
through the reduction of oxygen-dependent free radical damage and indirectly through bio-
logical HIF-1 complex signaling. The tumor re-oxygenation which occurs normally after RT
also increases oxidative stress, leading to endothelial sensitization at the tumor level [16–18].
It is believed that transiently relieving tumor hypoxia during radiotherapy (RT) could sig-
nificantly improve treatment outcome [19]. Previous in vitro studies have shown that
increased oxygen presence even just a few milliseconds before or after RT significantly
increases radiation-induced cancer cell damage [20]. There have been numerous previous
attempts to reoxygenate tumors to this effect, including hyperbaric oxygenation, inhaled car-
bogen, nitroimidazoles and other radiosensitizers; however, practical administration difficul-
ties, vasoconstriction and normal tissue toxicity have severely limited clinical translation [21–
23].
Recently, the technology of oxygen microbubbles (OMB) has made several substantial
advances, with the development of high-payload OMBs similarly formulated to micrometer-
sized ultrasound vascular contrast agents but comprising an oxygen gas core [24]. As such,
OMB have shown promise experimentally as an adjuvant cancer therapy in vivo to enhance
the efficacy of oxygen-dependent therapies. In radiotherapy, they would offer the ability for
localized oxygen delivery without the use of expensive dedicated equipment incompatible with
radiation therapy rooms. The robust oxygen-delivery potential of OMB is demonstrated by
their ability to sustain animals with otherwise fatal pneumothorax for over two hours [25], and
double the survival time of asphyxiated animals [26] when delivered intra-peritoneally. In a
mouse model of pancreatic cancer, OMB delivered by direct injection in the tumor have also
been shown to improve the efficacy of sonodynamic therapy [27, 28]. In chemotherapy, oxy-
gen and paclitaxel loaded microbubbles administered intravenously have shown promise as a
combination therapy in an ovarian mouse xenograft model [29].
We hypothesize that these oxygen microbubbles could also be used to transiently relieve
tumor hypoxia and thereby improve RT outcome if administered prior to treatment so that
additional oxygen is present during radiation treatment. As a first proof of principle demon-
stration, in this work, we assess the potential of oxygen microbubbles to increase dissolved
oxygen saturation in hypoxic solutions in vitro, increase tumor oxygenation in a rat fibrosar-
coma in vivo after direct injections, and improve tumor control after RT.
Material and methods
Microbubble manufacturing and characterization
All glassware was cleaned with an Alconox detergent purchased from Sigma-Aldrich
(St. Louis, MO) and rinsed with 18 MO-cm deionized water (Direct-Q, Millipore; Billerica,
MA). A concentrated (10x) phosphate-buffered saline (PBS) solution from Sigma-Aldrich
(St. Louis, MO) was diluted to normal concentration with deionized water and vacuum filtered
through a 0.2 μm nylon membrane filter (Whatman, Kent, United Kingdom). Phospholipid
1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC) was purchased from NOF (Tokyo,
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Japan), and polyoxyethylene-40 stearate (PEG-40S) was purchased from Sigma-Aldrich
(St. Louis, MO). Oxygen and nitrogen gas were purchased from Airgas (Airgas, Radnor, PA).
DSPC and PEG-40S were weighed in dry form, mixed in a 9:1 molar ratio, and added to the
filtered PBS solution to achieve a final lipid concentration of 12 mg/mL. A technique used by
Feshitan et al. [25] was implemented to dissolve the DSPC and PEG-40S into the PBS solution
and create a homogenous lipid solution. After adding the DSPC and PEG-40S, the mixture
was heated to 65 ˚C and homogenized using a Branson 450 sonifier (Danbury, CT) with an
output power of 25% total capability. The solution was sonicated until it appeared translucent
and then stored in the refrigerator at 4 ˚C. Oxygen microfoam was created from a process
design developed by Swanson et al. [30] to produce large volumes of oxygen microbubbles.
The process developed was used to create oxygen microbubbles specifically, but the methodol-
ogy is the same to produce nitrogen microbubbles with the exchange of oxygen for nitrogen
gas. The process comprised an ultrasonic horn reactor enclosed in a water-cooled, continu-
ous-flow chamber (Branson, Danburry, CT). The lipid solution was kept cool with ice packs
and combined with room temperature oxygen in the reactor. The lipid solution flow rate was
nearly double the flow rate of oxygen. Full sonication power was used in the reactor to emulsify
the oxygen gas and the sonicated solution was collected in a cooling column to separate the
oxygen microbubbles (bottom) from the macrofoam (top). The column was extracted into
60-mL syringes and centrifuged to further concentrate the oxygen microbubbles. The 60-mL
syringes were placed in an Eppendorf 5804 centrifuge (Hauppauge, NY) and centrifuged at
150 relative centrifugal force (RCF) for 4 min to yield a final concentration of ~ 70 vol%. The
concentrated oxygen microbubble foam was transferred into 20-mL glass serum vials (Whea-
ton, Millville, NJ), sealed with an oxygen headspace, and stored at 5 ˚C. The remaining centri-
fuged lipid solution was recycled and the process was repeated until the desired volume of 70
vol% oxygen microbubbles was produced. The concentration and size distribution of the oxy-
gen microbubbles (OMBs) (n = 3 independent samples) were measured using the Coulter
Counter method (Coulter Multisizer III, Beckman Coulter, Indianapolis, IN). The same meth-
odology described above was used to make concentrated nitrogen microbubbles (NMBs) by
just replacing the oxygen gas with room temperature nitrogen gas.
To extract microbubbles from a vial to be used in experiments, they were slowly pulled into
a syringe through a 20-gauge needle, while a bag filled with 100% oxygen was connected to
another needle in the vial top (to avoid creating a vacuum in the vial that could compromise
the bubbles’ integrity, as well as minimize the introduction of room air into the vial).
Fig 1. (Color online) example of acoustic angiography maximum intensity projections around tumors (tumor size
denoted with dashed yellow lines) in a rat fibrosarcoma allograft, with tortuous angiogenesis extending beyond the
tumor margins (red arrows). The small tumor (a) is also shown to be more enhanced, denoting its higher perfusion
compared to the larger tumor (b).
https://doi.org/10.1371/journal.pone.0195667.g001
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In vitro oxygen release
A fiber-optic oxygen sensor (Oxymicro, WPI, Sarasota, FL) was used to measure the dissolved
oxygen content in de-ionized water before and after microbubble injection. Prior to use, the
device was calibrated according to manufacturer’s instructions for a standard two-point cali-
bration in oxygen-free water and water vapor saturated air. Calibration for automatic tempera-
ture compensation was not performed since all experiments were performed in quick
succession at room temperature (centrally maintained at 22˚C).
For the measurement, a beaker with 70 mL of partially degassed de-ionized water contain-
ing a magnetic stirrer was placed on a stir plate for continuous mixing and the fiber-optic mea-
surement device recorded continuously before, during, and after OMB and NMB injections.
Injections consisted of 300 μL undiluted OMB or NMB. Experiments were repeated thrice
with independent vials of OMB or NMB and measurements were recorded continuously
before and for at least 5 min post microbubble injection. The maximum change in dissolved
oxygen saturation over the 5 min post-injection was compared between OMB and NMB
groups.
Animal model for all in vivo studies
All animal procedures were approved by the Institutional Animal Care and Use Committee of
the University of North Carolina at Chapel Hill and performed in accordance with the Guide
for the Care and Use of Laboratory Animals of the National Institutes of Health. Female Fisher
344 rats with subcutaneous fibrosarcoma (FSA) tumor allografts were used in all in vivo exper-
iments. This model was chosen as the development of hypoxia in these FSA tumors has been
extensively characterized [31–34]. These previous studies demonstrate hypoxia through EF5
and pimonidazole immunostaining, in addition to direct detection of pO2 in the tumor tissue
with microelectrodes. Results demonstrate moderate hypoxia throughout much of the tumor
and more severe hypoxia towards the tumor center. Briefly, tumor allografts grew after subcu-
taneous implantation on the right flank of 1 mm3 fibrosarcoma (FSA) tissue freshly resected
from donor tumor-bearing rats. Animals were used for experiments 2–3 weeks after implanta-
tion, when tumors were around 1 cm in diameter. The following standardized anesthesia pro-
tocol was followed for all tumor hypoxia measurements and for radiotherapy treatment
studies. Anesthesia was induced by placing the animals in an induction box for 3 min to
breathe 5% vaporized isoflurane with pure oxygen as the carrier gas. Anesthesia was main-
tained by having the animals breathe 2.0–2.5% isoflurane with medical air as the carrier gas for
the remainder of the experiment. The timing of this anesthesia protocol and the use of medical
air for the primary carrier gas allowed for consistent tumor hypoxia measurements and mini-
mized changes in blood oxygenation due to pure oxygen breathing rather than microbubble
intervention. The animals’ temperatures were maintained throughout the experiments using a
heated platform. When ultrasound imaging was used to evaluate tumor volume (unrelated to
measuring tumor hypoxia), animals were anesthetized using vaporized isoflurane (initially 5%
for induction, then 2–2.5%) with oxygen carrier gas.
In vivo oxygen release
Fisher rats with FSA tumors were anesthetized as described above, and the tumor area was
shaved. Tumor oxygenation was measured continuously in real-time using a validated optical
spectroscopy technique based on the absorbance of oxyhemoglobin and deoxyhemoglobin
(Zenascope, Zenalux Biomedical, Durham, NC). Fig 2 shows a schematic of the experimental
set-up for these measurements. Each experiment was capped at one hour from the start of
anesthesia. Prior to any intervention, a stable baseline was ensured by waiting 25 min from the
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start of anesthesia. An oxygen challenge, defined as changing the isoflurane carrier gas from
medical air to pure oxygen for 3 min, served as a positive control to ensure that an increase in
blood oxygenation could be measured reliably in the tumor. Tumor hypoxia level was mea-
sured continuously before and after the following interventions:
Fig 2. Experimental procedures. a) Schematic of the experimental set-up used for in-vivo hypoxia modulation measurements using the Zenascope system. b)
Schematic of tumor volume assessment via B-mode ultrasound imaging. Two cross-sectional images were acquired and lengths a, b and c were used to calculate tumor
volume. c) Radiotherapy pre and post-imaging experimental protocol.
https://doi.org/10.1371/journal.pone.0195667.g002
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1. OMB administration: 500 μL undiluted OMB injected intra-tumorally slowly over 30 s
(n = 4);
2. Nitrogen microbubble (NMB) administration (negative control): 500 μL undiluted NMB
injected intra-tumorally slowly over 30 s (n = 4).
The primary objective of this experiment was to characterize the ability of intratumoral
OMB administration to reoxygenate FSA tumors, and a secondary objective was to confirm
baseline hypoxia in this tumor model.
Radiotherapy experiments
Animals were anesthetized with isoflurane and oxygen carrier gas and positioned on a heated
pad, similarly to Fig 2. Two-dimensional B-mode ultrasound imaging was used to calculate
tumor volume (Acuson Sequoia 512, Mountain View, CA). The largest tumor cross-sections
in the sagittal and transverse planes were selected and saved after moving the transducer along
these directions on a 3D motion stage. Tumor volumes were then calculated using the ellipsoid
volume formula, V ¼ 4
3
p a b c, where V is the calculated tumor volume, a is half the measured
tumor width on the sagittal plane, b is half the measured tumor width on the transverse plane,
and c is half the measured tumor depth (taking the average between the sagittal and transverse
planes), Fig 2.
For a fixed dose of RT, it is well established that tumor control is strongly correlated to the
initial tumor volume on the day of treatment [35–41]. Since this study aims to evaluate the fea-
sibility of using OMB to improve radiotherapy outcome (tumor control), a matched study
design with respect to initial tumor volume on the day of radiotherapy was chosen to limit the
animal numbers needed. Since both the effect size of OMB and OMB dosing per tumor size
are unknown prior to the study, this strategy allows to see how the results scale with respect to
tumor volume and can then serve as a basis for a larger study (see Discussion for a full
explanation).
For this reason, care was taken to match initial tumor sizes on the RT day between treat-
ment groups. Tumor volume matching was achieved by implanting a few extra animals to
allow selecting the closest tumor volumes possible and ordering animals into similarly sized
groups after imaging, then randomizing treatment group assignment within these ordered cat-
egories. To minimize other biological variability within each experimental round, all animals
were ordered on the same day (of similar age), had the same time to acclimatize to the vivar-
ium before tumor implantation, were implanted on the same day from the same donor tumor,
and were treated on the same day. Hydration and wet food packs were given to all animals irre-
spective of treatment (or no treatment) group. The experimental rounds resulting from this
matching protocol are summarized in Table 1 and described hereafter.
Table 1. Experimental rounds for the radiotherapy experiments.
RT RT + OMB RT + NMB OMB alone No treatment
ROUND 1 n = 2 n = 2 n = 2
ROUND 2 n = 4 n = 4 n = 4 n = 4 n = 4
Animals were matched according to initial tumor volume on the day of radiotherapy, and experiments were repeated in two separate rounds: round 1 consisted of n = 2
animals per group and round 2 of n = 4 animals per group (where the experimental group conditions of ‘OMB alone’ and ‘No treatment’ were also added). Within each
experimental round, the animals were the same age, had the same amount of time to acclimatize to the vivarium before tumor implantation, were implanted on the
same day from the same donor tumor, and were treated on the same day.
https://doi.org/10.1371/journal.pone.0195667.t001
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A total of 18 animals were matched between radiotherapy treatment groups, 1) RT alone, 2)
RT+OMB and 3) RT+NMB as described above, in two rounds of experiments (n = 2 per group
in the first round, then n = 4 per group in the second round, total of n = 6 per group). Radio-
therapy consisted of a single 15 Gy dose of 6 MV photons (2 cm x 2 cm field size) delivered
using a clinical linear accelerator (Siemens Healthcare, Malvern, PA), following a previously
described protocol from our group [42]. Animals were anesthetized as described above (stan-
dardized protocol with medical air as the carrier gas) and positioned on a heating pad on top
of the clinical accelerator table. The skin around the tumor was gently extended and taped so
that the tumor was positioned outward from the body to avoid irradiating vital organs, and a 1
cm thick tissue-mimicking bolus was placed on top of the tumor to correct for normal tissue
attenuation of the radiation field meant for deeper tumors. The patient table height was
adjusted using light field crosshair projected on paper prior to the start of radiation therapy.
Animals in the groups receiving microbubbles were injected with 1 mL undiluted OMB or
NMB intra-tumorally immediately prior to the start of RT (since we are using a clinical linear
accelerator for treatment, in practice it takes 1 min to leave the treatment room and start the
treatment protocol). Following RT, tumor volume was measured using B-mode ultrasound as
previously described every 3 days for 31 days, as shown in Fig 2, or until the tumor reached 2.5
cm in the largest dimension, at which point animals were humanely sacrificed. Animals were
sacrificed via isoflurane overdose followed by thoracotomy as a secondary means of
euthanasia.
Effect of OMB administration in the absence of radiotherapy
During the second round of radiotherapy experiments, an additional two conditions were
tested: no treatment (n = 4) and OMB alone without RT (n = 4) and all animals in this round
were also matched for initial tumor volume as previously described.
Data analysis and statistical methods
All data are presented as mean ± standard deviation unless otherwise stated. Statistical signifi-
cance was set a priori at p<0.05 (). For in vitro and in vivo oxygen release measurements, the
Fig 3. In vitro oxygen microbubble characterization. a) Measured oxygen microbubble size distribution, displayed with a
diameter bin size of 0.032 μm, as mean ± standard deviation (gray area) from 3 independent samples; b) Measured change in
oxygen % saturation in vitro after 300 μL OMB (n = 3) or NMB (n = 3) injection into 70 mL partially degassed water
(p<0.05).
https://doi.org/10.1371/journal.pone.0195667.g003
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maximum difference in dissolved oxygen content after microbubble injection was compared
between the nitrogen and oxygen groups using a Student’s t-test. For radiotherapy experi-
ments, matched statistical comparison tests on the RT ‘tumor control time’, defined as the
time (in days) to reach maximum tumor burden (animals below the maximum tumor burden
at day 31 were included as day 32), between the treatment groups were performed: either
repeated measures ANOVA with Newman-Keuls multiple comparison post-test after confirm-
ing normality, or Friedman test with Tukey’s post-test after negative normality test.
Results
Microbubble characterization and in vitro oxygen release
Microbubble concentration was measured as 1.3 (±0.4) × 109 mL-1 and median bubble size
was around 4 μm, as shown in Fig 3A. In vitro dissolved oxygen saturation measurements
were significantly increased with the addition of 300 μL OMB into 70 mL water, by
14.2 ± 7.2%, compared to adding NMB (p = 0.04, n = 3 independent samples).
In vivo oxygen release results
Consistent real-time oxygenation dynamics were recorded using a non-invasive spectroscopic
measurement system by assuring prior to any intervention that sufficient time was given to
achieve a stable baseline during anesthesia. OMB were shown to increase tumor oxygenation,
whereas NMB lowered tumor oxygenation (Fig 4). Tumors used for this study ranged in diam-
eter from 5mm– 17mm, approximately matching the range of tumor sizes used for subsequent
radiotherapy experiments.
The average baseline percent hemoglobin saturation across all 8 tumors used for this exper-
iment was 55 ± 30% (range from 0–83% hemoglobin saturation). These data demonstrate that
the FSA model used here is indeed hypoxic. It is important to mention, however, a limitation
of the Zenalux measurement system. This system measures hemoglobin saturation via optical
spectroscopy. Therefore, it cannot accurately measure hypoxia deep within tissue due to the
limited penetration depth of light. And thus, for large tumors we are likely measuring hemo-
globin saturation only at the outer edge of the tumor rather than the center, biasing our values
to be higher than what would be observed at the tumor’s center. We believe that the percent
hemoglobin saturation reported here is conservative, and the tumors’ centers were likely more
hypoxic than what we report.
Radiotherapy results
Table 2 details all results from the radiotherapy experiments, for both rounds and including all
controls.
In Round 2, we included two additional control groups (No treatment and OMB alone,
n = 4/group) to ensure that the OMB administration did not influence tumor growth in the
absence of RT. Indeed, no significant difference was shown in tumor control between the ani-
mals receiving no treatment and those having received a single OMB administration in the
absence of any radiation treatment, as shown in Fig 5. Note: these controls were not included
in Round 1 of this study. Therefore, the number of animals and range of tumor sizes tested for
these control groups did not match the entire range of tumor sizes used for the radiation treat-
ment groups (RT, RT+NMB, and RT+OMB). As such, we have not drawn direct comparisons
between tumor control time of the No treatment and OMB only groups (Fig 5) with those of
the three radiation treatment groups (Fig 6).
Oxygen microbubbles improve radiotherapy tumor control
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From the animals receiving RT, 17/18 successfully completed the study (one of the rats in
the RT alone group died during anesthesia prior to the completion of the RT treatment proto-
col and was therefore excluded from the analysis). Initial RT results show that intra-tumoral
OMB improve tumor control after radiotherapy (p<0.05, n = 6 per group), Fig 6, and that ini-
tial tumor size significantly affects RT outcome, Table 2.
Discussion
OMB modulate tumor hypoxia
In this study, we demonstrate the oxygen payload of OMB in vitro and in vivo, before showing
that they can be used to significantly improve radiotherapy tumor control in a fibrosarcoma
Fig 4. Change in tumoral oxygenation with intra-tumoral injection of OMB or NMB. The time to peak was found
to be 97 s after injection on average, and the OMB-induced increase in tumoral oxygenation lasted for over 18 min on
average (our protocol’s maximum 1 h experiment time meant that we could not wait for a complete return to baseline
in some cases). A) Average peak change in tumoral hemoglobin saturation after OMB or NMB administration (n = 4/
group). B) Individual data points showing pre- and post-injection values. This demonstrates baseline hypoxia in all
tumors (0–83% hemoglobin saturation across all 8 tumors).
https://doi.org/10.1371/journal.pone.0195667.g004
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model in vivo. In vitro, the addition of OMB to hypoxic solution increases the amount of dis-
solved oxygen, as expected, and has significantly higher effect than that of the NMB control.
The very slight increase shown with NMB is due to the fact that these microbubbles were
added to hypoxic solutions and measurements were collected over a 5 min period, so the liquid
uptakes oxygen molecules through its surface area in contact with ambient air over this time
(gas exchange towards equilibrium). In vivo, direct OMB injections into fibrosarcoma tumors
are shown to significantly increase tumoral oxygenation, whereas the NMB injection control
had the opposite effect. This increase is very fast (peaks around 90 s post injection) and the
remains elevated for over 15 min, which is consistent with the improved tumor control
observed when combining RT with OMB administration in vivo.
Table 2. Individual datapoints for radiotherapy tumor control times (in days) stratified by matched initial tumor size for each treatment group, showing RT effect
size depends on initial tumor volume.
Matched initial tumor volume
(cm3)
Tumor control (in days) for the different treatment groups Increase in tumor control between RT
and RT+OMB
No treatment
(n = 4)
OMB alone
(n = 4)
RT
+ NMB
(n = 6)
RT
(n = 6)
RT
+ OMB
(n = 6)
In days:
(RT+OMB)—
RT
As percentage (%):
(RT+OMB) / RT  100–
100
ROUND
2
0.1 ± 0.0 32 32 32 32 32 0 0
0.3 ± 0.1 25 19 32 32 32 0 0
0.6 ± 0.1 10 19 22 22a 31 9 41
0.8 ± 0.1 10 10 22 22 28 6 27
ROUND
2
1.7 ± 0.2 10 16 22 6 38
2.8 ± 0.3 7 7 10 3 43
aAnimal died prior to experimentation end, value replaced from the NMB group since no overall difference was found between these two groups.
https://doi.org/10.1371/journal.pone.0195667.t002
Fig 5. A single oxygen microbubble administration alone does not influence tumor control. No significant
difference was found between the no treatment and oxygen microbubble group in the absence of any radiotherapy
(n = 4 per group). Box-and-whisker plots represent all data from the No treatment and OMB alone controls.
https://doi.org/10.1371/journal.pone.0195667.g005
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Fig 6. Tumor control time comparison between RT groups. OMB significantly improve RT outcome, whereas NMB
as controls do not (n = 6 per group). Box-and-whisker plots show all data from the three radiotherapy treatment
groups.
https://doi.org/10.1371/journal.pone.0195667.g006
Fig 7. Plot of gain in tumor control time against initial tumor volume, the confounding variable. An on/off effect
(threshold) is observed around 0.5 cm3 initial tumor volume. Below this size, tumors are controlled for 31 days with
RT alone. Above this size, tumors are large enough that RT alone cannot control them for 31 days, and therefore, OMB
administration can provide a substantial improvement in tumor control time. Additionally, the benefit offered by
OMB administration diminishes as initial tumor volume exceeds ~2 cm3. Given our study design, the slope describing
the inverse relationship between improvement in tumor control and initial tumor volume (above the threshold value
of 0.5 cm3) could in theory guide optimal OMB dosing with respect to tumor volume (confounder) in order to
maximize tumor control benefit for a given RT dose.
https://doi.org/10.1371/journal.pone.0195667.g007
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Radiotherapy improvement dependency on initial tumor volume
The results show that for a fixed RT dose and fixed OMB dose, the gain in tumor control time
depends on initial tumor volume, Table 2. As expected, we found that OMB administration
offered the greatest benefit for intermediately sized tumors (initial volume 0.6–1.7 cm3). Over
this size range, we observed survival benefits of 6–9 days (OMB+RT vs. RT alone), Table 2 and
Fig 7. Conversely, for very small tumors (<0.5 cm3 initial volume), the tumors likely have not
yet developed extensive hypoxia, and the radiotherapy dose is already very efficient for tumor
control. Thus, OMB do not significantly improve the RT efficacy for small tumors (Fig 7). This
observation is also biased by the fact that our observation time was capped at 31 days, resulting
in right censoring of all tumors that were still controlled by that time. For very large tumors
(>2 cm3 initial volume), the absolute gain in tumor control (in days) drops (Fig 7). Since these
are likely to be very hypoxic, and we are always injecting the same OMB dose, this is probably
not enough to reoxygenate these large tumors efficiently, thus limiting therapeutic gain. Inter-
estingly, when comparing the increase in tumor control offered by OMB administration as a
percentage of that offered by RT alone, we find fairly consistent improvement of ~35% for all
tumors larger than a threshold initial volume of 0.5 cm3 (Table 2, rightmost column).
With further optimization, we do believe that OMB administration holds the potential to
offer meaningful improvements in RT-mediated tumor control over a wide range of tumor
volumes. Here, OMB did not improve RT outcomes for those rats with small tumors simply
because the RT dose administered was already sufficient to provide a near complete response.
We hypothesize that if the RT dose was reduced for this cohort of animals, we would still be
able to achieve complete tumor regression through the administration of OMB. This is attrac-
tive since lowering the RT dose would reduce exposure of healthy tissue to radiation and limit
associated side effects. Similarly, we believe that we could achieve more substantial control of
large tumors by either increasing the OMB dose, RT dose, or both.
Limitations and future work
A limitation of this study is the relatively small sample size used in the assessment of OMB
administration for improved RT. Nevertheless, our results are consistent between two
completely independent rounds of experiments, and the benefit offered by OMB administra-
tion is large enough to be statistically significant despite the relatively small sample size. It is
reasonable to assume that optimization of the dosages and administration can result in even
greater improvement in tumor control. Now that a first demonstration has been established
including a comparison to NMB administration, a future study could concentrate on establish-
ing the radiotherapy dose-modifying factor (DMF) resulting from OMB (i.e. the reduction in
RT dose required to achieve the same tumor control probability when OMB are administered
as an adjunct therapy). To do so, animals are randomized between the RT alone and RT
+OMB groups, and the RT dose necessary to control 50% of tumors is calculated from logisti-
cal regression for each group; DMF is then calculated as the ratio between these RT doses. Nev-
ertheless, we estimate that a comprehensive assessment like the one described above requires
n = 100 animals from the preliminary data presented here, and thus is not warranted until fur-
ther OMB administration optimization is undertaken (see next Discussion section Potential
for clinical translation).
Throughout this study we used a rat FSA tumor model previously characterized to develop
hypoxic tumors. We confirmed baseline hypoxia via spectroscopic measurement of hemoglo-
bin saturation. However, a limitation is that we did not confirm tumor hypoxia with a second
method (e.g. immunostaining of key hypoxia markers). In future work, we plan to characterize
tumor-size-dependent hypoxia and the effect of OMB administration on hypoxia in more
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detail using histology. We are also interested in studying in more detail the effect of tumor vol-
ume on the efficiency of OMB-mediated reoxygenation.
Potential for clinical translation
Despite considerable progress in early detection and treatment options in multiple cancers
over the last decade, cancer remains difficult to treat in advanced disease stages and radioresis-
tance and recurrence at the primary tumor site remain significant clinical challenges.
Direct tumoral injections. A number of solid tumors are accessible for direct injections
clinically. In particular, head and neck cancer treated with external beam radiation therapy are
particularly hypoxic [43, 44] yet shallow enough for direct injections. Furthermore, more
deeply seated tumors such as those of the pancreas, liver, or colon can be accessed for intratu-
moral injection with ultrasound, endoscopic ultrasound or computed tomography image guid-
ance [45]. Additionally, a direct access for OMB with RT can be found in brachytherapy
(clinically approved) which uses guiding tubes to feed radiation sources inside solid tumors
where they irradiate for a few seconds before being retracted or are left implanted for lower
irradiation over time [46]. Therefore, this direct tumoral injection of OMB could potentially
be clinically translatable in the long term through brachytherapy co-administration (through
one of the guiding tubes) or some needle accessible solid tumors with external beam radiation.
In human clinical studies, intratumoral injections of 20–40% of the total tumor volume
have been reported [45, 47]. Here, we provided a consistent intratumoral OMB dose of 0.5
mL, regardless of tumor volume. It is promising that we found substantial survival benefit for
intermediately sized tumors (e.g. 1.7 cm3), where the OMB injection volume corresponded to
28% of the tumor volume and was therefore within the clinically achievable range. Future
efforts will be aimed at optimizing OMB dose with respect to baseline tumor hypoxia and
tumor volume, after which we anticipate being able to achieve substantial reoxygenation with
relevant OMB dose volumes across a wide range of tumor sizes.
Intravenous administration. Clinically, fractionated dose RT treatment plans, where
smaller doses of radiation are administered repeatedly typically five days a week over the
course of several weeks or months, were developed to spare healthy tissue toxicity, taking
advantage of the better repair capability of healthy tissue compared to tumor cells. Oxygen
microbubbles are similarly formulated to microbubble ultrasound contrast agents used for
imaging, but comprise an oxygen gas core instead of heavy molecular weight gases. Due to
their micrometer size scale, similar to that of a red blood cell, microbubble contrast agents are
confined to the vascular space after being intravenously administrated and serve as an ultra-
sound blood pool marker. Depending on the pressure of the incident ultrasound wave, micro-
bubbles will respond by either stably oscillating or by bursting.
Therefore, local release of oxygen from OMB following intravenous administration could
be achieved using focused ultrasound in the tumor region. This would be minimally invasive
and greatly advantageous in the context of fractionated dose RT. Such local reoxygenation
may allow for similar tumor control with even smaller radiation doses or fewer total treat-
ments. We have previously demonstrated in vitro that ultrasound application significantly
enhances oxygen delivery from OMB [48].
In addition to the potential use of ultrasound for image-guided locally triggered oxygen
release in the tumor, its ability to make microbubbles oscillate also offers a useful therapeutic
target in relation to RT. Indeed, it has been shown with (non-oxygen) microbubbles that stable
cavitation oscillation under ultrasound in the vasculature of the tumor prior to RT increases
radiation damage to these tumor vessels in a mouse model of prostate cancer treated with
radiotherapy [49]. In addition to inducing tumor cell death, RT also damages the endothelium
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of tumor vasculature, leading to additional tumor damage as it loses its blood supply network
post-treatment [50, 51]. As such, endothelial sensitization using acoustically active agents such
as microbubbles could offer an additional therapeutic target, as they mechanically oscillate
near vessel boundaries under appropriate ultrasound conditions. Importantly, this promising
result was achieved with non-oxygen microbubbles, so we anticipate that the additional target
of hypoxia modulation would further improve these results as they target a complementary,
radiosensitizing pathway.
Nevertheless, intravenous administration requires OMB that are stable enough to reach the
tumor and retain their oxygen gas before being disrupted by ultrasound locally. In principle,
the oxygen payload of OMBs would be retained for a longer duration in circulation if the car-
rier gas is pure oxygen rather than air. Additionally, the OMB formulation used in this work
was designed to achieve rapid oxygen release for peritoneal microbubble oxygenation [25, 26].
The OMBs could be reformulated to increase circulation persistence and oxygen payload
delivery to the tumor vasculature following intravenous administration.
Particular impact in RT. Finally, two specific radiotherapy targets merit further mention
with respect to OMB hypoxia modulation.
First, stereotactic radiosurgery (SRS) and stereotactic body radiotherapy (SBRT) involve
delivery of one or a few large dose fractions (e.g., 8–20 Gy) to the tumor volume. This
approach has shown particularly promising results for inoperable early stage tumors (e.g., lung
and prostate cancers) that are small, while sparing surrounding normal tissue from irradiation.
However, many tumors are hypoxic and thus radio-resistant. The SRS/SBRT procedures use
only a few fractions and cannot take advantage of radiotherapy-induced tumoral re-oxygen-
ation as the conventionally fractionated RT (with 30 daily fractions) can. For fractionated RT,
the surviving hypoxic cancer cells after one irradiation dose are re-oxygenated and so less hyp-
oxic at the time of the next dose [52]. Since this is not the case for SRS and SBRT, hypoxia is
deemed an even more important adjuvant therapeutic target for these treatments [53].
Secondly, 40% of patients are anemic prior to receiving RT and RT also often induces ane-
mia [54–56]. This has important implications for tumoral hypoxia, since the decreased ability
of blood to carry oxygen will also make the tumor resistant to radiation damages. It has been
demonstrated that anemia is associated with lower RT local tumor control in head and neck
cancers [57]. As such, an oxygen delivery system that does not rely on red blood cells such as
oxygen microbubbles could significantly benefit this patient subpopulation in particular [58,
59].
Conclusions
In conclusion, our data show that oxygen microbubbles administered by direct intra-tumoral
injection in fibrosarcoma allografts in vivo are capable of increasing tumoral oxygenation sig-
nificantly for tens of minutes, whereas control nitrogen microbubble injection reduces
tumoral oxygenation. Furthermore, a preliminary study with a fixed microbubble dose and
radiotherapy protocol shows that oxygen microbubbles significantly improve radiotherapy
tumor control. This constitutes the first demonstration that OMB can improve RT outcome.
The tumor control time improvement is heavily dependent on the initial tumor volume as
expected for any fixed dose RT study. Smaller tumors are expected to be less hypoxic and easier
to control to the end of our predetermined study observation period with radiotherapy alone,
whereas large tumors are likely more hypoxic.
The ability to measure the real-time dynamics of OMB-induced tumor hypoxia modulation
could also be used to inform other tumor re-oxygenation adjuvant therapies, as well as opti-
mize the dose and timings for RT. As such, future studies will concentrate on investigating
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administration routes and dosages. In particular, the ability to administer OMB intravenously
remains most attractive due to being minimally invasive and potentially allowing for an
image-guided, ultrasound-triggered release mechanism locally. This in turn offers the largest
clinical translation applicability with repeated fractionated dose radiotherapy protocols and
could harness endothelial sensitization as an additional therapeutic-enhancing mechanism.
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